Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
October 2019
-
Lessons from a blind chef
Christine Hà lost her vision at a young age – and went on to become an award-winning chef.
-
Media ReleaseNovartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mgResults from a Phase IIb dose-finding study show an average complete response rate of 42% for doses 240 mg and 72 mg ligelizumab at Week 12 compared with 26% for those taking 300 mg Xolair’s dose (…
-
Key ReleaseNovartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs afliberceptIn two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of…
-
Oncology Careers: Life Changing Purpose
-
Media ReleaseAveXis presents updated STRONG data at WMSOlder patients (≥ 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follow-up…
-
Women in Science: Lauren Abrey
Learn about the career of our Global Medical Affairs Head for Solid Tumors and Rare Diseases.
-
Key ReleaseNovartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrumPhase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)[1] Novartis plans FDA submission…
-
Media ReleaseNovartis and Microsoft announce collaboration to transform medicine with artificial intelligenceMultiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercializedNovartis to establish…
September 2019
-
Word on the Street: What is cell and gene therapy?
We leave the lab to find out what people know about cell and gene therapy.
-
Media ReleaseNovartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthmaOnce-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint[1] PALLADIUM is part of Phase III PLATINUM clinical development program,…
-
Media ReleaseNovartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthmaOnce-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint[1],[2] IRIDIUM is largest study in Phase III PLATINUM clinical…
-
Key ReleaseNovartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patientsIn MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs. fulvestrant alone in postmenopausal women (HR=0.724; p=0.00455)[1] Kisqali is the only…
Pagination
- ‹ Previous page
- 1
- …
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- …
- 152
- › Next page